Logo image of OPT

OPTHEA LTD-SPON ADR (OPT) Stock Fundamental Analysis

USA - NASDAQ:OPT - US68386J2087 - ADR

3.41 USD
+0.23 (+7.23%)
Last: 3/17/2025, 8:00:02 PM
Fundamental Rating

2

Overall OPT gets a fundamental rating of 2 out of 10. We evaluated OPT against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of OPT have multiple concerns. While showing a medium growth rate, OPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OPT has reported negative net income.
In the past year OPT has reported a negative cash flow from operations.
OPT had negative earnings in each of the past 5 years.
In the past 5 years OPT always reported negative operating cash flow.
OPT Yearly Net Income VS EBIT VS OCF VS FCFOPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -175.60%, OPT is not doing good in the industry: 86.49% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -175.6%
ROE N/A
ROIC N/A
ROA(3y)-138.57%
ROA(5y)-94.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OPT Yearly ROA, ROE, ROICOPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

OPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OPT Yearly Profit, Operating, Gross MarginsOPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

OPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OPT has more shares outstanding
The number of shares outstanding for OPT has been increased compared to 5 years ago.
Compared to 1 year ago, OPT has a worse debt to assets ratio.
OPT Yearly Shares OutstandingOPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OPT Yearly Total Debt VS Total AssetsOPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -9.32, we must say that OPT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OPT (-9.32) is worse than 71.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.32
ROIC/WACCN/A
WACC9.32%
OPT Yearly LT Debt VS Equity VS FCFOPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 1.57 indicates that OPT should not have too much problems paying its short term obligations.
OPT's Current ratio of 1.57 is on the low side compared to the rest of the industry. OPT is outperformed by 81.23% of its industry peers.
A Quick Ratio of 1.57 indicates that OPT should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.57, OPT is not doing good in the industry: 80.35% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.57
OPT Yearly Current Assets VS Current LiabilitesOPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.42% over the past year.
The Revenue for OPT has decreased by -25.06% in the past year. This is quite bad
OPT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.88% yearly.
EPS 1Y (TTM)16.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.76%
Revenue 1Y (TTM)-25.06%
Revenue growth 3Y22.04%
Revenue growth 5Y2.88%
Sales Q2Q%-60.45%

3.2 Future

The Earnings Per Share is expected to grow by 24.88% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 384.85% on average over the next years. This is a very strong growth
EPS Next Y56.03%
EPS Next 2Y33.14%
EPS Next 3Y24.08%
EPS Next 5Y24.88%
Revenue Next Year-37%
Revenue Next 2Y1620.09%
Revenue Next 3Y1036.13%
Revenue Next 5Y384.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OPT Yearly Revenue VS EstimatesOPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
OPT Yearly EPS VS EstimatesOPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OPT Price Earnings VS Forward Price EarningsOPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OPT Per share dataOPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

OPT's earnings are expected to grow with 24.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.14%
EPS Next 3Y24.08%

More info and screens

0

5. Dividend

5.1 Amount

OPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPTHEA LTD-SPON ADR

NASDAQ:OPT (3/17/2025, 8:00:02 PM)

3.41

+0.23 (+7.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2025-02-28/bmo
Earnings (Next)08-28 2025-08-28/amc
Inst Owners40.24%
Inst Owner Change0%
Ins Owners1.22%
Ins Owner ChangeN/A
Market Cap524.75M
Analysts78
Price Target6.57 (92.67%)
Short Float %0.37%
Short Ratio13.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3%
PT rev (3m)19.52%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-75.68%
EPS NY rev (3m)-59.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-20%
Revenue NY rev (3m)-40%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5969.9
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0
BVpS-1.1
TBVpS-1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-138.57%
ROA(5y)-94.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 48.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.57
Altman-Z -9.32
F-Score1
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)21.93%
Cap/Sales(5y)17.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.76%
EPS Next Y56.03%
EPS Next 2Y33.14%
EPS Next 3Y24.08%
EPS Next 5Y24.88%
Revenue 1Y (TTM)-25.06%
Revenue growth 3Y22.04%
Revenue growth 5Y2.88%
Sales Q2Q%-60.45%
Revenue Next Year-37%
Revenue Next 2Y1620.09%
Revenue Next 3Y1036.13%
Revenue Next 5Y384.85%
EBIT growth 1Y-10.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.69%
EBIT Next 3Y15.54%
EBIT Next 5Y22.71%
FCF growth 1Y-46.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.8%
OCF growth 3YN/A
OCF growth 5YN/A